KRAS

Amgen plans 2020 filing for FDA approval of KRAS drug sotorasib
Amgen plans 2020 filing for FDA approval of KRAS drug sotorasib
Fierce Biotech
Amgen
FDA
sotorasib
KRAS
Flag link:
Amgen teases 'promising' phase 2 data for closely watched KRAS prospect
Amgen teases 'promising' phase 2 data for closely watched KRAS prospect
Fierce Biotech
Amgen
clinical trials
non-small cell lung cancer
KRAS
sotorasib
Flag link:
Amgen sees no 'significant delays' from pandemic to novel KRAS cancer drug
Amgen sees no 'significant delays' from pandemic to novel KRAS cancer drug
Fierce Biotech
Amgen
KRAS
AMG 510
COVID-19
clinical trials
cancer
Flag link:
Verastem pens KRAS-focused drug licensing deal with Chugai
Verastem pens KRAS-focused drug licensing deal with Chugai
Fierce Biotech
Verastem
KRAS
cancer
Chugai
Flag link:
KRAS craze sees Merck put $2.5B biobucks down for Taiho, Astex licensing deal
KRAS craze sees Merck put $2.5B biobucks down for Taiho, Astex licensing deal
Fierce Biotech
Merck
Taiho
Astex
R&D
KRAS
Flag link:
As Amgen zeroes in on cancer, neuroscience pipeline under the ax
As Amgen zeroes in on cancer, neuroscience pipeline under the ax
Fierce Biotech
Amgen
KRAS
oncology
cancer
Neuroscience
Flag link:
Novartis sends second wagon after KRAS gold rush
Novartis sends second wagon after KRAS gold rush
Endpoints
Novartis
KRAS
drug discovery
Flag link:
Mirati sets date for closely watched clinical KRAS readout
Mirati sets date for closely watched clinical KRAS readout
Fierce Biotech
Mirati Therapeutics
KRAS
MRTX849
Amgen
cancer
Flag link:
As developers work on cracking KRAS, Germany's Boehringer has quietly begun testing its pan-KRAS drug in humans
As developers work on cracking KRAS, Germany's Boehringer has quietly begun testing its pan-KRAS drug in humans
Endpoints
KRAS
cancer
Boehringer Ingelheim
Flag link:
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More
Xconomy
ESMO
PARP inhibitors
prostate cancer
KRAS
Seattle Genetics
AstraZeneca
Merck
GSK
Amgen
breast cancer
Roche
Pfizer
Flag link:
Colon cancer proves tougher target for Amgen's KRAS drug
Colon cancer proves tougher target for Amgen's KRAS drug
Biopharma Dive
Amgen
colon cancer
ESMO
KRAS
Flag link:
At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More
At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More
Xconomy
WCLC
lung cancer
KRAS
AMG 510
Amgen
RET
Merck
Keytruda
AstraZeneca
Imfinzi
Blueprint Medicines
Eli Lilly
Flag link:
Mirati and Novartis Pair Up to Evaluate Drug Combinations to Target KRAS G12C Mutations
Mirati and Novartis Pair Up to Evaluate Drug Combinations to Target KRAS G12C Mutations
BioSpace
Mirati Therapeutics
Novartis
KRAS
solid tumors
Flag link:
3 takeaways from cancer's biggest conference
3 takeaways from cancer's biggest conference
Biopharma Dive
Amgen
KRAS
accelerated approvals
Turning Point Therapeutics
Keytruda
Opdivo
ASCO 2019
Flag link:
3 Cancer Stocks Given a Lift by Amgen
3 Cancer Stocks Given a Lift by Amgen
Motley Fool
Amgen
KRAS
AMG 510
Mirati Therapeutics
Array Biopharma
Gilead Sciences
ASCO 2019
Flag link:
Did This Biotech Giant Just Find The Key To An 'Undruggable' Protein?
Did This Biotech Giant Just Find The Key To An 'Undruggable' Protein?
Investors Business Daily
Amgen
AMG 510
KRAS
ASCO 2019
lung cancer
colon cancer
Flag link:
Early cancer drug data give Amgen hope it's 'cracked KRAS code'
Early cancer drug data give Amgen hope it's 'cracked KRAS code'
Biopharma Dive
ASCO 2019
KRAS
lung cancer
colorectal cancer
pancreatic cancer
Amgen
AMG 510
Flag link:
Ionis Earns $28 Million from AstraZeneca for a New Drug to Treat Cancer
Ionis Earns $28 Million from AstraZeneca for a New Drug to Treat Cancer
Yahoo
Ionis
AstraZeneca
AZD4785
KRAS
cancer
Flag link: